
Revisit Every OncLive On Air Episode From October 2026
In case you missed any, read a recap of the episodes of OncLive On Air that aired in October 2026.
In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in October 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!
FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia
In this episode of OncLive On Air, Ruben Mesa, MD, FACP, of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Charlotte, North Carolina, outlined the significance of the August 2026 FDA approval of ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia. He detailed the key efficacy and safety findings from the phase 3 SURPASS-ET trial (NCT04285086) that supported the approval and looked ahead to other research that could continue to shape this space.
Breast Cancer Survivorship Care Demands Rigorous Systemic Change
In this episode of Breast Cancer Briefing, host Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, sat down with Hil Moss, MBA, MPH, co-founder and chief executive officer of OncoveryCare and a breast cancer survivor, to examine the often-overlooked gap in breast cancer survivorship care. Drawing on her own diagnosis at age 28, Moss framed survivorship as a care-model design problem and detailed OncoveryCare’s virtual, survivorship-trained model that integrates with oncology teams to address the physical, mental health, and behavioral needs of survivors.
Novel MEK Inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer
In this episode of OncLive On Air, Vincent Chung, MD, of City of Hope in Duarte, California, discussed the development of the MEK inhibitor atebimetinib (IMM-1-104) in metastatic pancreatic cancer. He explained the agent’s unique mechanism of action and improved tolerability relative to earlier-generation MEK inhibitors, reviewed safety and efficacy findings from a phase 2a trial (NCT05585320) combining it with modified gemcitabine and nab-paclitaxel (Abraxane), and previewed how the ongoing phase 3 MAPkeeper-301 trial (NCT07562152) may affect the treatment paradigm.
Navigating Patient-Centric Treatment Administration Strategies in Myeloma
In this episode of OncLive On Air, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of the Cleveland Clinic in Ohio, and Sikander Ailawadhi, MD, of Mayo Clinic in Rochester, Minnesota, discussed how on-body subcutaneous administration is shaping multiple myeloma management. In the second episode of a 3-part series, they explored how on-body administration of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection is setting the stage for future patient-centric treatment approaches.
The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer
In this episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts, was joined by Joyce F. Liu, MD, MPH, also of Dana-Farber Cancer Institute and Harvard Medical School, to survey the rapidly expanding landscape of novel ovarian cancer therapies. They covered the next generation of antibody-drug conjugates, antibody-drug conjugate (ADC) resistance mechanisms and sequencing, cell cycle targets such as CCNE1 and KIF18A, and emerging strategies for rare histologic subtypes including low-grade serous and clear cell disease.
Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers
In this episode of OncLive On Air, Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute in Durham, North Carolina, discussed the emergence of B7-H4 as an attractive ADC target in gynecologic cancers. She reviewed phase 1 BEHOLD-1 trial (NCT06431594) data in platinum-resistant ovarian cancer, the rationale for combining mocertatug rezetecan with dostarlimab-gxly (Jemperli) in the phase 1/2 BEHOLD-2 trial (NCT06796907), BLUESTAR study (NCT05123482) results for puxitatugsamrotecan, and a proactive approach to managing topoisomerase 1 payload toxicities.
Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma
In this episode of OncLive On Air, the final episode in this 3-part series, Drs Faiman and Ailawadhidiscussed how on-body subcutaneous administration could enable select at-home treatment for patients with multiple myeloma. They explained how they are integrating on-body administration of isatuximab for subcutaneous injection into practice following its July 2026 FDA approval and how the method could support at-home treatment in the future.
Biology-Driven Care and AI Tools Steer the Future of Breast Oncology
In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, of Norton Cancer Institute in Louisville, Kentucky, was joined by Jame Abraham, MD, FACP, of Cleveland Clinic, to discuss practice-changing advances in breast cancer. They examined first-line sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) from the phase 3 ASCENT-04 trial (NCT05382286), chemotherapy de-escalation from the phase 3 OPTIMA trial (ISRCTN42400492), the May 2026 FDA approvals of fam-trastuzumab deruxtecan-nxki (Enhertu) in early HER2-positive disease based on the phase 3 DESTINY-Breast05 trial (NCT04622319), and the growing role of artificial intelligence in oncology.
FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer
In this episode of OncLive On Air, Erika P. Hamilton, MD, of Sarah Cannon Research Institute in Nashville, discussed the FDA approval of tucatinib (Tukysa) plus trastuzumab (Herceptin) and pertuzumab (Perjeta) for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy.
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
In this episode of OncLive On Air, Triparna Sen, PhD, of the Ohio State University Comprehensive Cancer Center—James in Columbus, and Jacob Sands, MD, of Dana-Farber Cancer Institute and Harvard Medical School, weighed the role of lurbinectedin (Zepzelca) in a shifting small cell lung cancer landscape. They discussed the phase 3 IMforte trial (NCT05091567) of lurbinectedin added to atezolizumab (Tecentriq) maintenance in extensive-stage disease, the negative phase 3 LAGOON trial (NCT05153239) that led to the withdrawal of the agent’s second-line indication, and the significance of the phase 3 DeLLphi-305 trial (NCT06211036) of tarlatamab (Imdelltra) plus durvalumab (Imfinzi).
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
In this episode of Breast Cancer Briefing, Dr Nunnerysat down with Sarah L. Sammons, MD, of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center in Baltimore, Maryland, to discuss the management of HER2-positive metastatic breast cancer and brain metastases. They reviewed central nervous system–penetrant therapy, the phase 3 HER2CLIMB-05 trial (NCT05132582) behind the FDA approval of tucatinib added to trastuzumab and pertuzumab maintenance, and how maintenance strategies differ by hormone receptor status, including the phase 3 PATINA trial (NCT02947685) regimen for estrogen receptor–positive disease.
Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer
In this episode of OncLive On Air, Lyudmila Bazhenova, MD, and Sandip Patel, MD, both of the University of California San Diego Moores Cancer Center, explained why calling a tumor simply “MET positive” is no longer specific enough in non–small cell lung cancer (NSCLC). They distinguished MET protein overexpression, detected by immunohistochemistry and defining eligibility for telisotuzumab vedotin-tllv (Emrelis), from MET exon 14 skipping mutations and MET amplification detected by next-generation sequencing, and reviewed data from the phase 2 LUMINOSITY trial (NCT03539536) and the ongoing phase 3 TeliMET NSCLC-01 trial (NCT04928846).
Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC
In this episode of OncLive On Air, Aditya Juloori, MD, of the University of Chicago in Illinois, and David Carbone, MD, PhD, of The Ohio State University, explored how factors beyond PD-L1 expression—including histology, co-occurring genomic alterations, brain metastases, and patient fitness—can guide first-line regimen selection in driver-negative metastatic NSCLC. They highlighted dual checkpoint inhibition for higher-risk populations, including the CheckMate 9LA regimen (NCT03215706) of nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy, and discussed the implications of STK11 and KEAP1 alterations and the management of baseline brain metastases.
Board Review 2026: Top Hematology/Oncology Topics to Know
In this episode, OncLive On Air partnered with Two Onc Docs hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, for a board exam preparation guide ahead of the American Board of Internal Medicine hematology and oncology certification exams. They offered test-day strategies and a rapid-fire review of high-yield topics across lung, breast, and genitourinary cancers, malignant and benign hematology, and testable areas such as black box warnings, research methodology, and supportive care.
How Allergists Fit Into the Systemic Mastocytosis Management Equation
In this episode of OncLive On Air, Nathan A. Boggs, MD, PhD, of the Uniformed Services University of the Health Sciences in Bethesda, Maryland, broke down how allergists and immunologists fit into the multidisciplinary diagnosis and treatment of systemic mastocytosis. He highlighted key strategies for symptom management and how agents such as avapritinib (Ayvakit), bezuclastinib (CGT9486), and elenestinib (BLU-263) have affected and will continue to shape the treatment paradigm.
Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML
In this episode of OncLive On Air, Fadi Haddad, MD, of The University of Texas MD Anderson Cancer Center in Houston, discussed the importance of consistent daily adherence to oral TKIs for achieving deep responses, treatment-free remission, and long-term survival in chronic myeloid leukemia. He outlined common barriers to adherence and the use of dose reductions and therapy changes to manage adverse effects, and explored where liquid and orally disintegrating formulations such as imatinib oral solution (Imkeldi) may help patients who cannot swallow pills.
Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
In this episode of Oncology Unplugged, Dr Parkwas joined by Petros Grivas, MD, PhD, FASCO, of Fred Hutch Cancer Center and the University of Washington School of Medicine in Seattle, Washington, to review key bladder cancer data from the 2026 ESMO Congress. They discussed the phase 3 VOLGA trial (NCT04960709) of neoadjuvant durvalumab (Imfinzi) plus enfortumab vedotin-ejfv (Padcev) with or without tremelimumab (Imjudo), the contrast between the positive phase 3 NIAGARA trial (NCT03732677) and other perioperative studies, and data across metastatic and non–muscle-invasive disease.
Related to this article








